Keros Therapeutics Inc (NASDAQ: KROS) open the trading on Thursday, with great promise as it jumped 0.96% to $10.52, before settling in for the price of $10.42 at the close. Taking a more long-term approach, KROS posted a 52-week range of $9.77-$73.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -50.00%. Meanwhile, its Annual Earning per share during the time was -111.11%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 0.22%. This publicly-traded company’s shares outstanding now amounts to $39.26 million, simultaneously with a float of $32.86 million. The organization now has a market capitalization sitting at $426.14 million. At the time of writing, stock’s 50-day Moving Average stood at $40.52, while the 200-day Moving Average is $49.72.
Keros Therapeutics Inc (KROS) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Keros Therapeutics Inc’s current insider ownership accounts for 18.87%, in contrast to 83.33% institutional ownership. According to the most recent insider trade that took place on Aug 13 ’24, this organization’s Director sold 250,000 shares at the rate of 44.01, making the entire transaction reach 11,002,500 in total value, affecting insider ownership by 119,522. Preceding that transaction, on Aug 13 ’24, Company’s Director sold 250,000 for 44.01, making the whole transaction’s value amount to 11,002,500. This particular insider is now the holder of 119,522 in total.
Keros Therapeutics Inc (KROS) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.35 per share during the current fiscal year.
Keros Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 0.22% and is forecasted to reach -4.83 in the upcoming year.
Keros Therapeutics Inc (NASDAQ: KROS) Trading Performance Indicators
Let’s observe the current performance indicators for Keros Therapeutics Inc (KROS). It’s Quick Ratio in the last reported quarter now stands at 19.03. The Stock has managed to achieve an average true range (ATR) of 2.32. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 655.60.
In the same vein, KROS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -5.21, a figure that is expected to reach -1.36 in the next quarter, and analysts are predicting that it will be -4.83 at the market close of one year from today.
Technical Analysis of Keros Therapeutics Inc (KROS)
[Keros Therapeutics Inc, KROS] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 8.75% While, its Average True Range was 1.79.
Raw Stochastic average of Keros Therapeutics Inc (KROS) in the period of the previous 100 days is set at 1.19%, which indicates a major fall in contrast to 9.97% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 85.28% that was lower than 216.19% volatility it exhibited in the past 100-days period.
